Sector Expert: Eun Yang

Jefferies & Co.



Recent Quotes

"OPK's interim Phase 2 data for Lagova in pediatric growth hormone deficiency (GHD) is encouraging."

— Eun Yang, Jefferies & Co. (6/24/14)
more >

"OPK's 4Kscore is positioned to reduce the number of unnecessary prostate biopsies."

— Eun Yang, Jefferies & Co. (6/3/14)
more >

"OPK's Q1/14E cash of ~$156M should be sufficient into 2015."

— Eun Yang, Jefferies & Co. (5/13/14)
more >

"OPK's YE/13 cash of ~$186M should be sufficient thru H1/16."

— Eun Yang, Jefferies & Co. (3/4/14)
more >

"Preclinical pharmacokinetic data for OPK's FVIIa-CTP are encouraging."

— Eun Yang, Jefferies & Co. (2/28/14)
more >

"PSTI has enough cash for ~2 years."

— Eun Yang, Jefferies & Co. (11/21/13)
more >

"OPK will be in the top 25 market cap companies on the TASE."

— Eun Yang, Jefferies & Co. (9/9/13)
more >

"OPK's cash of ~$169M should be sufficient into 2015."

— Eun Yang, Jefferies & Co. (8/12/13)
more >



Due to permission requirements, not all quotes are shown.